The Oncology Brothers and Harold J. Burstein, MD, PhD, discuss clinical approaches to treating patients with locally advanced HER2+ breast cancer.
Dato-DXd May Be Next SOC in First-Line TNBC
Datopotamab deruxtecan significantly enhanced survival rates in first-line treatment for metastatic triple-negative breast cancer.
Cardiovascular Considerations in Breast Cancer Treatment and Survivorship
Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.
PFS Benefit Occurs With Trastuzumab Rezetecan in HER2+ Breast Cancer
Trastuzumab rezetecan may represent a promising practice-changing therapeutic in this breast cancer population based on data from HORIZON-Breast01.
Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Sacituzumab Tirumotecan Prolongs PFS Vs Chemo in Pretreated Breast Cancer
Data from OptiTROP-Breast02 support sac-TMT as a new treatment option for those with hormone receptor–positive, HER2-negative breast cancer.
ASCENT-03 Trial Supports Standard Use of Sacituzumab Govitecan in mTNBC
Although the ORR was similar among patients treated with sacituzumab govitecan vs chemotherapy for TNBC, the DOR was higher with sacituzumab govitecan.